Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 6, Pages 1214-1223Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2012.59
Keywords
biglycan; tumour endothelial cells; tumour angiogenesis
Categories
Funding
- Ministry of Education, Science and Culture of Japan
- Grants-in-Aid for Scientific Research [23390457, 23659930, 21592566, 21591655, 23792096] Funding Source: KAKEN
Ask authors/readers for more resources
BACKGROUND: We isolated tumour endothelial cells (TECs), demonstrated their abnormalities, compared gene expression profiles of TECs and normal endothelial cells (NECs) by microarray analysis and identified several genes upregulated in TECs. We focused on the gene encoding biglycan, a small leucine-rich repeat proteoglycan. No report is available on biglycan expression or function in TECs. METHODS: The NEC and TEC were isolated. We investigated the biglycan expression and function in TECs. Western blotting analysis of biglycan was performed on sera from cancer patients. RESULTS: Biglycan expression levels were higher in TECs than in NECs. Biglycan knockdown inhibited cell migration and caused morphological changes in TECs. Furthermore, immunostaining revealed strong biglycan expression in vivo in human tumour vessels, as in mouse TECs. Biglycan was detected in the sera of cancer patients but was hardly detected in those of healthy volunteers. CONCLUSION: These findings suggested that biglycan is a novel TEC marker and a target for anti-angiogenic therapy. British Journal of Cancer (2012) 106, 1214-1223. doi: 10.1038/bjc.2012.59 www.bjcancer.com Published online 28 February 2012 (C) 2012 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available